NCT02152631 2026-02-06
JUNIPER
Eli Lilly and Company
Phase 3 Active not recruiting
Clinical Trials
34 trialsNCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02296125 2026-01-09
FLAURA
AstraZeneca
Phase 3 Completed
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT00130728 2021-01-14
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 3 Completed
NCT01667562 2019-12-20
ESSENCE
Hoffmann-La Roche
Phase 3 Completed
NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
NCT01523587 2019-02-15
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT00364351 2018-01-25
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Sanofi
Phase 3 Completed
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT00036647 2018-01-10
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Astellas Pharma Inc
Phase 3 Completed
NCT00040183 2018-01-10
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Astellas Pharma Inc
Phase 3 Completed
NCT01351415 2017-09-18
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed
NCT01360554 2017-05-24
ARCHER 1009
Pfizer
Phase 3 Completed
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02031744 2017-03-14
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01377376 2016-12-07
ATTENTION
Kyowa Kirin Co., Ltd.
Phase 3 Terminated
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT01456325 2016-11-02
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Genentech, Inc.
Phase 3 Completed
NCT01887886 2016-11-02
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche
Phase 3 Completed
NCT01328951 2016-10-28
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT00883779 2015-12-14
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00373425 2015-09-17
RADIANT
Astellas Pharma Inc
Phase 3 Completed
NCT01183858 2015-08-19
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
Hoffmann-La Roche
Phase 3 Completed
NCT01342965 2015-02-24
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
Hoffmann-La Roche
Phase 3 Completed
NCT00556322 2015-02-23
A Study of Tarceva (Erlotinib) and Standard of Care Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed
NCT00556712 2015-02-11
A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed
NCT00718315 2015-01-15
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
Hoffmann-La Roche
Phase 3 Completed
NCT00091663 2014-03-04
A Study to Evaluate Tarceva in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 3 Completed
NCT00457392 2013-10-29
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
Pfizer
Phase 3 Completed
NCT00673049 2013-07-24
NSCLC
Pfizer
Phase 3 Terminated
NCT00047736 2013-06-21
A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer
Genentech, Inc.
Phase 3 Completed